Natera, Inc. is a diagnostic company focusing on cfDNA tests in women's health, organ health, and oncology. Natera's MRD test, Signatera, demonstrated strong growth, with a 64% increase in processed ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Natera (NTRA) has moved into focus after a favorable patent ruling against ArcherDx and Invitae, royalty income tied to MRD products, broad uptake of its Signatera test, and recent progress toward ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability ...
Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings This recently published, real-world, multi-center, retrospective study analyzed 233 ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA ...
Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter can be downloaded here.
Hosted on MSN
Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer
Natera Inc. (NASDAQ:NTRA) is one of the best growth stocks to buy now. On September 30, Natera announced the publication of a validation study for its personalized molecular residual disease test, ...
Prospective follow-up of 43 women ≥70 years with stage I–III ER+/HER2− disease managed with primary endocrine therapy incorporated Signatera ctDNA testing at baseline and every 3–6 months. Baseline ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results